throbber
_ _ Remington The
`Scnence and Practice
`. ~
`of Pharmacy
`
`Volume II
`
`
`
`.
`
`a
`
`J
`
`.
`
`.
`
`.
`
`_
`
`‘
`
`.
`
`.
`
`.
`
`"
`
`,
`
`.
`
`.
`
`.
`
`_
`
`.
`
`
`
`.
`
`.
`
`-_.
`
`.
`
`_
`
`‘._
`
`_
`
`_
`
`.\
`
`_
`
`_
`
`_
`
`Celltrion Exhibit 1016
`Page 1
`
`

`

`1 9TH
`EDITION
`
`Remington
`PraCtiCe of
`
`ALFONSO R GENNARO
`Chairman of the Editorial Board
`and Editor
`
`Celltrion Exhibit 1016
`Page 2
`
`

`

`The Science and
`Pharmacy
`
`1995
`
`MACK PUBLISHING COMPANY
`Easton, Pennsylvania 18042 .
`
`Celltrion Exhibit 1016
`Page 3
`
`

`

`Entered according to Act of Congress,‘ 1n the year 1885 by Joseph P Remington,
`in the Office of the Librarian of Congress, at Washington DC
`~
`
`Copyright 1889,1894,1905,19071917,by Joseph P Remington
`
`Copyright 1926, 1936, by the Joseph P Remington Estate
`
`Cop'ylight 1948, l 951, by The Philadelphia College of Pharmacy and Science
`
`Copyright 1956,1960,1965,1970,1975,1980,1985,1990,1995, by The Philadelphia Co11ege of
`Pharmacy and Science
`
`All Rights Reserved
`
`Library of Congress Catalog Card No. 60-53334
`
`ISBN 0-9 1 2734-04-3
`
`The use of stntctural formulas from USAN and the USPDictionary of Drug Names is by
`permission of The USP Convention. The Convention is not responsible for any inaccuracy
`contained herein.
`
`NOTICE—This text is not intended to represent, nor shall it be interpreted to be, the equivalent
`of or a substitute for the qfiicial United States Pharmacopeia (USP) and/ or the National
`Formulary (NF). In the event of any diferenee or discrepancy between the current oficiat
`USP or NF standards of strength, quality, purity, packaging and Labelingfor drugs and
`representations of them herein, the context and efiect of the oflicial compendia shall prevail.
`
`Printed in the United States of America by the Mack Printing Company, Easton, Pennsylvania
`
`Celltrion Exhibit 1016
`Page 4
`
`

`

`l
`
`e
`
`r
`
`CHAPTER 89
`Ophthalmic Preparations
`
`Gerald Hecht, PhD
`Senior Director, Pharmaceutical Sciences
`Alcoa Laboratories
`Fort Wonh, TX 76101
`
`Ophthalmic preparations are sterile products essentially
`free from foreign particles, suitably compounded and pack-
`aged for instillation into the eye. Ophthalmic preparations
`include solutions, suspensions,-"ointments and solid dosage
`forms. . The solutions and Suspensions are, for the most part,
`aqueous. Ophthalmic ointments usually contain awhite pet-
`rolatum-mineral oil base.
`Ophthalmic preparations can be grouped broadly into two
`divisions of major significance to the pharmacist These 111-
`clude single or multidose prescription products and the cat-
`egory described as. OTC o r over-the-counter ophthalmic
`products The latter group has been subjected to a searching
`review and analysis by a body of experts as a part of the FDA's
`OTC Drug Review process.
`The single dominant factor characteristic of all ophthalmic
`products is the specification of sterility. Any product in-
`tended for use in the eye regardless of form, substance or
`intent must be sterile. This requirement increases the simi-
`larity between ophthalmic and parenteral proddcts, however
`the physiology of the human eye in many respects imposes
`more rigid formulation requirements. This will be consid-
`ered 1n the following discussion.
`Preparations intended for the treatment of eye disorders
`can be traced to antiquity Egyptian papyri writings describe
`eye medications. The Greeks and Romans expanded such
`uses and gave us the tenn-colly’n'a. Collyria refer collec-
`tively to materials which were dissolved in water, milk or egg
`white for use as eyedrops.
`In the Middle Ages collyria in—
`cluded mydriatic substances to dilate the pupils of milady' 5
`eyes for cosmetic purposes, thus the term belladonna or “beau-
`tiful lady.”
`'
`From the time of belladonna collyria, ophthalmic technol-
`ogy progressed at a pharmaceutical snail’s pace well into
`modern times.
`It was not until after the second World War
`that the concept of sterility became mandatory for ophthalmic
`solutions. Prior to World War II and continuing
`into the
`19405 very few ophthalmic preparations were available com-
`mercially or were described oflicially. The USP XIV, official
`in 1950, included only three ophthalmic preparations and all
`three were ointments.
`Preparations to be u s e d ” 1n the eye, either solutions or oint-
`ments, invariably were compounded
`in the community or
`hospital pharmacy and were intended for immediate (prescrip-
`tion) use. Such preparation and prompt use is reflected in
`the pharmaceutical literature of the times. The stability of
`ophthalmic preparations is discussed' 1n terms of days or a few
`months.
`-
`One of the most important attributes of ophthalmic prod-
`ucts is the requirement of sterilityu Even that, however, is a
`surprisingly recent event. The USP XV in 1955 was the first
`official compendium to include a sterility requirement for
`ophthalmic solutions. The FDA in 1953 adopted the posi-
`tion that a nonsterile ophthalmic solution was adulterated.
`Sterile ophthalmic products were, of course, available prior to
`the mid 19505, however the legal requirement of sterility
`dates only from 1955.
`The sterility requirements for ophthalmic ointments ap-
`peared first in the USP XVIII _ 777.d Supplement (1972).
`Prior to that date there was no legal requirement for a sterile
`
`ophthalmic ointment. This probably was due to the difficulty
`(at that time) of testing for sterility' 1n such nonaqueous sys-
`tems and also for the anticipated difficulties in sterilizing and
`maintaining sterile conditions during the manufacture and
`filling of ointments on a large scale.
`1.
`-
`
`Anatomy and Physiology of the Eye
`
`The human eye is a challenging subject for topical adminis-
`tration of drugs. The basis of this can be found in the anatomi-
`cal arrangement of the surface tissues and 111 the permeability
`of the cornea The protective operation of the eyelids and
`lacrimal system rs such that there is rapid removal of material
`instilled into the eye, unless the material IS suitably small 1n
`volume and chemically and physiologically compatible with
`surface tissues. Figures 11 and 21 include pertinent anatomy
`'
`of the human eye.
`Eyelids—The eyelids serve two purposes: mechanical
`protection of the globe and creation of an optimum milieu for
`the cornea. The eyelids are lubricated and kept fluid-filled by
`secretions of the lacrimal glands and specialized cells residing
`in the bulbar conjunctiva. The antechamber has the shape of
`a narrow cleft directly over the front of the eyeball, with
`pocket-like extensions upward and downward; The pockets
`are called the superior and inferior fornices (vaults), and the
`entire space, the cul-de-sac. The elliptical opening between
`the eyelids 15 called the palpebral fissure
`'
`Eyeball—The wall of the human eyeball (bulbus, globe) 1s
`composed of three concentric layers.
`1. The outer fibrous layer.
`2. A middle vascular layer—the uvea or uveal tract, consisting of the
`choroid, the ciliary body and the iris.
`.
`3. A nervous layer—the retina.
`The outer layer is tough, pliable but only slightly stretchable.
`In'its front portion—~theportion facing the outside world——
`the fine structure of the outer layer is so regular and the water
`content so carefully adjusted that it acts as a clear transparent
`window (the cornea).
`It is devoid of blood vessels. over
`the remaining two-thirds the fibrous coat is opaque (the
`“white” of the eye) and is called the sclera.
`It contains the
`microcirculation which nourishes the tissues of this anterior
`segment and is usually white except when irritated and vessel
`dilatation occurs.
`The eyeball houses an optical apparatus that causes in-
`verted reduced images of the outsideworld to form on the
`retina, which is a thin translucent membrane. The optical
`apparatus consists, in sequence, of the precorneal film, the
`cornea, the aqueous humor, the pupil, the crystalline lens, the
`vitreous humor and the retina. The aqueous and vitreous
`humors are layers of clear fluid or gel-like material interposed
`between the solid structures. The pupil, a round centric hole
`in a contractile membranous partition (called the iris), acts as
`the variable'aperture of the system. The crystalline lens is a
`refractive element with variable power controlled and sup-
`ported by a muscle incorporated in the ciliary body. The
`choroid is the metabolic support for the retina.
`The optical function of the eye calls for stability of its
`dimensions, which is provided partly by the fibrous outer coat;
`
`1563
`
`Celltrion Exhibit 1016
`Page 5
`
`

`

`ME'H‘OHJF‘Z
`
`MflnflHmHHHHfifi.P-EMO
`
`H
`
`1564
`
`CHAPTER 89
`
`EXCRETORY DUCT
`
`comuncnw
`CONJUNCTIVAL
`SAC
`(
`
`WOLFRING‘S
`GLANDS
`
`CRYPTS OF
`HENLE
`
`MEIBOMIAN
`GLANDS
`TARSAL PLATE
`
`‘GLANDS 0F
`ZEIS
`(SEBACEOUS)
`
`GLANDS 0F MOLL
`‘
`(SWEAT)
`
`VlTREOUS
`HUMQB
`
`Fig1. The eye: vertical section“
`
`more effective as a stabilizing factor is the intraocular pres-
`sure,.which is in excess of the pressure prevailing in the
`surrounding tissues. This intraocular pressure is the result
`of a steady'production of specific fluid, the aqueous humor,
`which originates from the ciliary processes and leaves the eye
`by an intricate system of outflow channels. The resistance
`
`LACRIMAL GLAND
`
`EXCRETOR‘r DUCTS
`
`NASAL '
`SEPTUM
`
`(LACRIMAL Pucm‘
`
`INFERIOR CONCHA
`
`' Fig 2. Nasolacrimalduct;1
`
`encountered during this passage and the rate of aqueous
`production are the principal factors determining the level of
`In addition to this hydromechani-
`the intraocular pressure.
`cal function, the aqueous humor acts as a carrier of nutrients,
`substrates and metabolites 'for the avascular tissues of'the eye.
`The bones of the skull join to form an approximately pyra-
`' mid-shaped housing for the eyeball, called the orbit.
`Conjunctiva—The conjunctiva] membrane covers the
`outer surface of the white portion of the eye and the inner
`aspect of the eyelids.
`In most places it is attached loosely
`and thereby permits free movement or the eyeball. This
`makes possible subconjunctival injections. ExCept for the
`cornea the conjunctiva is the most exposed portion of the eye.
`Lacrimal System—The conjunctival and corneal surfaces
`are covered and lubricated by a film of fluid secreted by the
`conjunctival and lacrimal glands. The secretion of the lacri-
`mal gland, the tears, is delivered through a number of fine
`ducts into the conjunctival fornix.‘ The secretion is a clear,
`watery fluid containing numerous salts, glucose, other organic
`compounds, approximately 0.7% protein and the enzyme,
`lysozyme. Small accessory lacrimal glands are situated in
`the conjunctival fornices. Their secretion suflices for lubrica-
`tion and cleansing under ordinary conditions and for maintain-
`ing a thin fluid film covering the cornea and conjunctiva (the
`precomeal film). The mucin—protein layer of the film is espe-
`cially important in maintaining the stability of the film. The
`main lacrimal gland- is called into play only on special
`occasions. The sebaceous glands of the eyelids secrete an
`oily fluid which helps to prevent overflowing of tears at the lid
`margin and reduces evaporation from the exposed surfaces of
`the eye by spreading over the tear film
`Spontaneous blinking replenishes the fluid film by pushing a
`thin layer of fluid ahead of the lid margins as they come
`together. The excess fluid is directed into the lacrimal
`lake—a small triangular area lying in the angle bound by the
`innermost portions of the lids. The skin of the eyelids is the
`thinnest in the body and folds easily, thus permitting rapid
`opening and closing of the palpebral fissures. The move-
`ment of the eyelids includes a narrowing of .the palpebral
`fissures in a zipper-like aetion from the lateral canthustoward
`the corners where the eyelids
`the medial canthus (canthi:
`meet). This aids the transport or movement of fluid toward
`the lacrimal lake
`Tears are drained from the lacrimal lake by two small
`tubes—the lacrimal canaliculi—which lead into the upper
`part of the nasolacrimal duct, the roomy beginning of which is
`called the lacrimal sac. The drainage of tears into the nose
`does not depend merely on gravity. Fluid enters and passes
`along the lacrimal canaliculi by capillary attraction aided by
`aspiration caused by contraction of muscle embedded in the
`eyelids. ‘.When the lids close, as in blinking, contraction of
`the muscle causes dilatation of the upper part of the lacrimal
`sac and compression of its lower portion. . Tears are thus
`aspirated into the sac, and any whichhave collected in its
`lower part are forced down the nasolacrimalduct toward its
`opening into .the nose. As the lids open, the muscle relaxes.
`The upper part of the sac then collapses and forces fluid into
`the lower part, which at the same time is released from
`compression. Thus, the act of blinking exerts a suction-force-
`pump action in removing tears from the lacrimal lake and
`emptying them into the nasal cavity. Lacrimation is induced
`reflexly by stimulation of nerve endings of the cornea or
`conjunctiva. - The reflex is abolished by anesthetization of the
`surface of the eye and by disorders affecting its nerve compo-
`nents
`The normal cul- de- -sac usually rs free of pathogenic organ-
`isms and often found sterile. The sterility may be due partly
`to the action of lysozyme in the tears, which normally destroys
`saprophytic organisms but has little action against pathogens.
`More eiTective in producing sterility may be the fact that the
`secretions, which are normally sterile as they leave the glands,
`constantly wash the bacteria, dust, etc, down in the nose. . In
`certain diseases the lacrimal gland, like other glandular struc-
`tures in the body, undergoes involution, with the result that
`
`Samsung Bioepis Exhibit 1016
`
`Celltrion Exhibit 1016
`Page 6
`
`

`

`OPHTHALMIC PREPARATIONS
`
`1565
`
`‘
`
`3 '
`
`.
`
`l
`
`'
`
`
`
`_
`
`.1.
`
`tonometer. Care must be used in applying the device to the
`cornea to avoid abrasion of the cornea Corneal abrasions
`sometimes result from wearing contact lenses. Every cor-
`neal abrasion' is subject to infection._ .
`-
`.
`-
`Bioavailability
`-
`.
`.
`..
`.. ‘-
`- Physical Consideration—Under normal conditions the
`human tear volume averages about 7 11L} The'estimated
`maximum volume of the cul-de-sac is about‘BO 11L with drain-
`age capacity far exceeding lacrimation rate. The outflow
`capacity accommodates the sudden large volume resulting
`from the instillation of an eyedrop.- Most commercial eye-
`drops range from 50 to 75 11L in volume, however, much' in
`excess of 50 11L probably is unable to enter the cul-de-sac.
`.Within the rabbit 'cul-de-sac, the drainage rate has been
`shown to be proportional to the instilled drop volume:
`Multiple drops administered at intervals produced higher drug
`concentrations.
`Ideally, a high concentration of drug in a
`minimum drop volume is desirable. Patton3 has shown that
`approximately equal tear-film concentrations result from the
`instillation of 5 1.1L of 1.61 ><v10'2 M pilocarpine nitrate or
`from 25 11L of 1.0 x 10 2Msolution. The 5 1.1L contains only
`38% as much pilocarpine, yet its bioavailability is greater due
`to decreased drainage less.
`There is a practical limit or limits to the concept of mini-
`mum dosage volume. There is a difficulty in designing and
`producing a dropper configuration which will deliver small
`volumes reproducibly. Also, the patient often cannot detect
`the administration of such a Small'volume. This sensation or
`lack of sensation is particularly apparent at the 5. 0—7. 5-1111
`dose-volume range. , '
`.
`The concept of dosage-volume drainage and cul— de-sac ca-
`pacity directly efl°ects the prescribing and administering of
`separate ophthalmic preparations. The first drug adminis-
`tered may be diluted significantly by the administration of the
`second. On this basis combination drug products for use in
`ophthalmology have considerable merit.
`Corneal Absorption
`Drugs administered by instilla-
`tion" must penetrate the eye and do so primarily through the
`cornea. Corneal absorption is much more effective than
`scleral or coniunctival absorption where rembval by blood
`vessels into the general circulation occurs.
`Many ophthalmic drugs are weak bases and are applied to
`the eye as aqueous solutions of their salts. The free base and
`the salt will be in an equilibrium which will depend on the pH
`andon the individual characteristics of the drug molecule.
`To aid in maintaining storage stability and solubility, the medi-
`cation may be acidic at the moment of instillation but, usually,
`the neutralizing action of the lacrimal fluid will convert it
`rapidly to the physiological pH range (approximately pH 7.4),
`at which there will be enough free base present to begin
`penetration of the corneal epithelium. Once inside the epi-
`thelium the undissociated free base dissociates immediately
`to adegree. The dissociated moiety then will tend to pen-
`etrate the stroma because it is water-soluble. At thejunction
`of the stroma and 'endothelium the same process that took
`place at the outer surface of the epithelium must occur again.
`Finally, the dissociated drug leaves the endothelium for the
`aqueous humor. Here it can readily diffuse to the iris and the
`'
`ciliary body, the site of its pharmacological actidn.
`‘ ‘
`The' cornea can be penetrated by 10115 to a small, but measur-
`able, degree. Under comparable conditions, the permeabili-
`ties are similar for all ions of small molecular _weight, which
`suggests that the passage is through extracellular spaces.
`The diameter of the largest particles which can ass across the
`cellular layers seems to be in the range 10—25
`An instilled
`drug is subject to protein binding in the tear fluid and meta-
`. bolic degradation by enzymes such as lysozyme, in addition to
`the losses by simple overflow and lacrimal drainage.
`Since the cornea' is a membrane including both hydrophilic
`and lipophilic layers, most effective penetration is obtained
`with drugs having both lipid and hydrophilic properties.
`Highly water soluble drugs penetrate less readily. As an
`
`.
`
`.
`
`the lacrimal fluid becomes scanty. Furthermore, changes in
`the conjunctival glands may- lead to alteration in the character
`of the secretion so that quality as well as quantity of tears may
`be abnormal. This may lead to symptoms of dryness, burn-
`ing and general discomfort, and may interfere with visual
`acuity.
`Precorneal Film—The cornea must be wet to be an opti-
`cally adequate surface ,when dry, it loses both its regular gloss
`and its transparency. The precomeai film, part of the tear
`fluid, provides this important moist surface.
`Its character
`depends on the condition of the corneal epithelium. The
`film, compatible with both aqueous and lipid ophthalmic prepa-
`rations, is composed of a thin outer lipid layer, a thicker
`middle aqueous layer and a thin inner mucoid layer.
`It is
`renewed during each blink and when blinking is suppressed,
`either by drugs or by mechanical means, it dries in patches.
`It seems to be unaffected by the addition of concentrations of
`up to 2% sodium chloride to conjunctival fluid. A pH below 4
`or above 9 causes derangement of the film. The film affects
`the movement of contact lenses and forms more easily on
`'
`glass than on plastic prostheSes.
`Cornea—The cornea, from 0. 5 to 1 mm thick, consists
`mainly of the following structures (from the front backwards):
`1. Corneal epithelium
`'
`2. Substantia propria (stroma).
`3. Corneal endothelium.
`'
`,
`The cornea is transparent to ordinary diffuse light, largely
`because of a special laminar arrangement of the cells and
`fibers and because of the absence of blood vessels.
`Cloudiness of the cornea may be due to any one of several
`factors including excess pressure in the eyeball as in glau-
`coma; scar tissue due to injury, infection or deficiency of
`oxygen or excess hydration such as may occur'during the
`wearing of improperly fitted contact lenses. A wound of the
`cornea usually heals as an opaque patch which can. be a
`permanent impairment of vision unless it is located in the
`periphery of the cornea.
`The chief refraction of light for. the eye occurs at the outer
`surface of the cornea where the index of refraction changes
`from that of air (1.00) to that of precorneal substance (1.38);
`Any alteration in its shape or transparency interferes with the
`formation of a clear image; therefore, any pathological pro-
`cess,- however slight, may interfere seriously with the resolv-
`ing power or visual acuity of the eye.
`The normal cornea possesses no blood vessels except at the
`comeoscleral junction. The cornea, therefore, must derive
`its nutrition by diffusion and must have certain permeability
`it also receives nourishmentfrom the fluid
`characteristics;
`circulating through the chambers of the eye and from the air.
`The fact that the normal cornea isdevoid of blood vessels is an
`important feature in surgical grafting. The corneal nerves do
`not supply all forms of sensation to the cornea. Pain and
`cold are well supplied. The pain fibers have avery low thresh-
`old, which makes the comea one of the most sensitive areas on
`It now is agreed generally that the
`the surface of the body.
`cornea possesses atrue sense of touch; nerve endings supply-
`-
`ing the sensation of heat are lacking
`The corneal epithelium provides an efficient barrier against
`bacterial invasion. Unless its continuity has been broken by
`an abrasion (a traumatic opening or defect in the epithelium)
`pathogenic bacteria, as a rule, cannot gain a foothold.
`Trauma, therefore, plays an important part in most of the
`infectious diseases of the cornea which occur exogenously.
`Any foreign body that either scratches the cornea or lodges
`and becomes irnbedded in the cornea is of serious moment
`because of the role it may play in permitting pathogenic
`bacteria to gain a foothold.
`A means of detecting abrasions on the corneal surface is
`If
`afforded by staining the cornea with sodium fluorescein.
`there is an abrasion on the epithelium, the underlying layer
`stains a brilliant green, so that even pinpoint abrasions show
`up quite clearly. Abrasion may occur during tonometry, that
`is, during the measurement of ocular tension (pressure) with a
`
`_
`
`_
`
`-,__. _-_._
`__-__
`
`.
`
`;
`
`.
`
`Celltrion Exhibit 1016
`Page 7
`
`

`

`. 0 Never use eye drops that have changed color.
`'
`’ ‘
`. 0
`Ifyou have more than one bottle of the same kind of drops, open
`.
`only one bottle at a time
`If you are using more than one kind of drop at the same time, wait
`0
`several minutes before use of other drops.
`0
`It may be helpful in use of the medicine
`positioning yourself‘ in front of a mirror.
`0 After instillation of drops, do not close eyes tightly and try not to
`blink more often than usual, as this removes the medicine from the place
`-'
`on the eye where it will be effective.
`:
`
`to practice use by
`
`How to .Use Ophthalmic Ointments
`Wash hands.
`.
`Remove cap from tube.
`With one hand, gently pull lower eyelid down.
`'
`While looking up, squeeze a small amount of ointment (about ‘A to
`1,3 in) inside lower lid. Be careful not to touch tip of tube to eye, eyelid,
`fingers, etc.
`' 5 Close eye gently and roll eyeball' in all directions while eye is closed
`Temporary blurring may occur.
`6. The closed eyelid may be rubbed very gently by a finger to distribute
`the drug throughout the fomix.
`'
`7. Replace cap on tube
`' 0 Take care to avoid contaminating cap when removed.
`0 When opening ointment tube for the first time, squeeze out the
`first 1/4” of ointment and discard as it may be too dry.
`0 Never touch tip of tube to any surface.
`'
`D
`If you have more than one tube of the same ointment, open only
`One at a time.
`o
`If you are using more than one kind of ointment at the same time,
`wait about 1 0 minutes before use of another ointment.
`0 To improve flow of ointment, hold tube in hand several minutes to
`warm before use.
`It may be helpful in use of the ointment to practice use by position-
`0
`, .
`ing yourselfin front of a mirror.
`Ophthalmic Solutions—This is by far the most common
`means of administering a drug to the eye. The USP describes
`59 ophthalmic solutions. By definition, all ingredients are
`completely in solution, uniformity is not a problem and there
`is little physical interference with vision. The principal disad-
`vantage of-‘ solutions is the relatively brief contact time'be-
`tween the medication and absorbing surfaces. Contact time
`may be increased to some extent by the inclusion of aviscosity
`increasing agent such as methylcellulose. . Inclusions of this
`sort are permitted by the USP. Aviscosity' in the range of 15
`to 25 cps is considered optimum for drug retention and visual
`comfort.
`Ophthalmic Suspensions—Suspensions are dispersions
`of finely divided, relatively insoluble drug substances in an
`aqueous vehicle containing suitable suspending and dispers-
`ing agents. There are 29 listed in the USP. The vehicle is,
`among other things, a saturated solution of the drug substance.
`Because of a tendency of particles to be retained in’the cul-de-
`sac, the contact time and duration of action of a suspension
`probably exceeds that of a solution. The drug is absorbed
`from solution and the solution concentration is replenished
`from retained particles. Each of these actions is a function
`of particle size, with solubility rate being favored by smaller
`size and retention favored by a larger size; thus, optimum
`activity should result from an optimum particle size.
`For aqueous suspensions the parameters of intrinsic solubil-
`ity and dissolution rate must be considered. The intrinsic
`Solubility determines the ambunt of drug actually in solution
`and available for immediate'absorption' upon instillation of the
`dose. As the intrinsic solubility of the drug increases, the
`concentration of the drug in the saturated solution surround-
`ing the suspended drug particle also' increases For this rea—
`son, any comparison of different drugs“ in su'spension systems
`should include their relative intrinsic solubilities. The ob-
`served differences in their biological activities may be 'as—
`cribed wholly or in part to the differences in this physical
`parameter; As the drug penetrates the cornea and the initial
`saturated solution becomes depleted, the particles must dis-
`solve to provide a further supply of the drug. The require-
`ment here is that the particles must undergo significant disso-‘
`
`1593.592“
`
`‘
`
`1566
`
`CHAPTER 89
`
`'
`
`example highly water soluble steroid phosphate esters pen-
`etrate the cornea poorly: ' Better penetration is achieved with
`the poorly soluble'but more lipophilic steroid alcohol; still
`greater absorption is seen with the steroid acetate form.
`In 1976 Lee and Robinson“ and in 1990, Lee5 presented‘a
`summary of the factors controlling precomeal‘ 'pildcarpin'e
`disposition and pilocarpine bioavailability in the rabbit eye.
`Combining experimental work and. computer simulation the
`investigators discussed the mechanisms competing with cor-
`Included were solution drain-
`neal absorption of pilocarpine.
`agé,‘ drug-induced vasodilation, nonconjunctival loss includ-
`ing uptake by the ~nictitating membrane, coniunctival
`absorption, induced lacrirnation and normal tear turnover.
`Subject to experimental conditions the relative effectiveness
`of the factors involved in precomeal drug removal are drain-
`age : vasodilation > nonconjunctival. loss > induced lacri-
`mation = conjunctival absorption .> normal tear turnover.
`The authors discuss the implications of the mechanisms of
`precomeal drug loss in the design of ocular drug—delivery
`systems including the effect of instilled drug volume on aque-
`ous humor concentration and the amount of drug available for
`systemic absorption. On an absolute basis a smaller volume
`allows more drug to be absorbed. For a given instilled con-
`centration the opposite is true; however, a smaller volume
`instilled remains more efiiéient, ie, the fraction of dose ab-
`sorbed is greater. Lang6 discusses the transcomeal route of
`absorption of a drug into the eye as that route most effective in
`bringing a given drug to the anterior portion of the eye.
`This route of absorption is enhanced by the waterglipid gradi-
`ent found in the cornea. As previously mentioned, the cor-
`the lipid-rich epithe-
`nea is composed of three general layers:
`lium, the lipid—poor stroma and the lipid-rich endothelium.
`Differential studies on the relative lipid contents of these three
`layers have shown that the corneal epithelium and the corneal
`endotheliumboth contain approximately 100 times as much
`lipid as the corneal stroma. This, coupledwith the physiologi-
`cal pH of 7.2 1.0.2 and its effect on ionizable drug molecules
`plays the most significantrole in corneal penetration.
`. Ophthalmic ointments generally produce greater bioavail-
`ability than the equivalent aqueous solution. Because of the
`greater contact time drug levels are prolonged and total drug
`absorption is increased.
`
`Types of Ophthalmic Products
`
`Administration—The instillation of eyedrops remains one
`of the less precise, yet one of the more accepted means of
`topical drug delivery. The method of administration is cum-
`bersome at best, particularly for the elderly, patients with
`poor vision who have difficulty seeing without eyeglasses and
`patients with other physical handicaps Perhaps, surpris-
`ingly, the majority of patients become quite adept at routine
`~
`instillation.
`The pharmacist should advise each patient to keep the
`following points in mind to aid' in the instillation of eyedrops
`or ointments:
`
`' How to Use Eyedrops‘
`
`1 Wash hands
`2. “nth one hand, gently pull lower eyelid down.
`If dropper: is separate, squeeze rubber bulb once while dropper is in
`. 3.
`bottle to bring liquid into dropper.
`4. Holding dropper above eye. drop medicine inside lower lid while
`looking up; do net touch dropper to eye or fingers.
`5. Release lower lid Try to keep eye open and not blink for at least 30
`seconds.
`If dropper' is separate, replace on bottle and tighten cap.
`6.
`if dropper' is separate, always hold it with tip down. -
`0
`0 Never touch dropper to any surface.
`0 Never rinse dropper.
`I When dropper' is at top of bottle, avoid contaminating cap when
`removed.
`'
`I When dropper is a permanent fixture on the bottle, ie, when
`supplied by a. pharmaceutical manufacuirer to the pharmacist, the. same
`rules apply to avoid contamination.
`'
`
`Celltrion Exhibit 1016
`Page 8
`
`

`

`Iution within the residence time of the dose' in the eye if any
`benefit is to be gained from their presence in the dosing
`system. -
`For a drug whose dissolution rate is rapid, the dissolution
`requirement may present few problems, but for a slowly soluble
`substance the dissolution rate becomes critical.
`If the disso-
`lution rate is not suficiently rapid to supply significant addi-
`tional dissolved drug, there is the possibility that the slowly
`soluble substance in suspension provides no more drug to the
`aqueous humor than does a more dilute suspension or a
`saturated solution of the substance in a similar vehicle.
`Obviously, the particle size of the suspended drug affects the
`surface area available for dissolution. Particle size also plays
`an important part in the irritation potential of the dosing
`system. This consideration is important, as irritation pro-
`duces excessive tearing and rapid drainage of the instilled
`dose. It has been recommended that particles be less than
`10 pm in size to minimize irritation‘to the eye.
`It should be
`kept in mind, however, that in any suspension system the
`effects of prolonged storage and changes in storage tempera-
`ture may cause the Smallest particles to dissolve and the
`largest particles to become larger.
`In summary, aquedus
`suspensions should, in general, give a more extended effect
`than aqueous solutions.
`The pharmacist should be aware of two potential difficulties
`inherent in suspension dosage forms.
`In the first instance
`dosage uniformity nearly always requires brisk shaking to
`distribute the suspended drug. Adequate shaking is a func-
`tion of the suitability of the suspension formulation but also,
`and most importantly, patient compliance. Studies have dem-
`onstrated that a significant number of patients may not shake
`the container at all, others may contribute a few trivial shakes.
`The pharmacist should stress the need of vigorous shaking
`whenever an ophthalmic suspension is dispensed:
`A second and infrequent characteristic of suspensions is the
`phenomenon of polymorphism or the ability of a substance to
`exist in seVeral different crystalline forms.

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket